These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24359151)

  • 1. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.
    Kaushik AK; Vareed SK; Basu S; Putluri V; Putluri N; Panzitt K; Brennan CA; Chinnaiyan AM; Vergara IA; Erho N; Weigel NL; Mitsiades N; Shojaie A; Palapattu G; Michailidis G; Sreekumar A
    J Proteome Res; 2014 Feb; 13(2):1088-100. PubMed ID: 24359151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential.
    Zimmer BM; Howell ME; Wei Q; Ma L; Romsdahl T; Loughman EG; Markham JE; Seravalli J; Barycki JJ; Simpson MA
    Horm Cancer; 2016 Aug; 7(4):260-71. PubMed ID: 27307252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
    Dai X; Shi X; Luo M; Li P; Gao Y
    BMC Cancer; 2023 Dec; 23(1):1241. PubMed ID: 38104097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).
    Li Y; Shi H; Zhao Z; Xu M
    BMC Urol; 2022 Oct; 22(1):162. PubMed ID: 36258196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer.
    Williamson SC; Mitter R; Hepburn AC; Wilson L; Mantilla A; Leung HY; Robson CN; Heer R
    Br J Cancer; 2013 Aug; 109(4):950-6. PubMed ID: 23880823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
    Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
    Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells.
    Putluri N; Shojaie A; Vasu VT; Nalluri S; Vareed SK; Putluri V; Vivekanandan-Giri A; Byun J; Pennathur S; Sana TR; Fischer SM; Palapattu GS; Creighton CJ; Michailidis G; Sreekumar A
    PLoS One; 2011; 6(7):e21417. PubMed ID: 21789170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.
    Wu G; Huang S; Nastiuk KL; Li J; Gu J; Wu M; Zhang Q; Lin H; Wu D
    Prostate; 2015 May; 75(7):777-782. PubMed ID: 25731771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic signatures of aggressive prostate cancer.
    McDunn JE; Li Z; Adam KP; Neri BP; Wolfert RL; Milburn MV; Lotan Y; Wheeler TM
    Prostate; 2013 Oct; 73(14):1547-60. PubMed ID: 23824564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
    Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
    Kuo KF; Hunter-Merrill R; Gulati R; Hall SP; Gambol TE; Higano CS; Yu EY
    Clin Genitourin Cancer; 2015 Feb; 13(1):10-6. PubMed ID: 25242417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.
    Armstrong K; Ahmad I; Kalna G; Tan SS; Edwards J; Robson CN; Leung HY
    Br J Cancer; 2011 Oct; 105(9):1362-9. PubMed ID: 21952621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
    Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
    Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
    Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
    [No Abstract]   [Full Text] [Related]  

  • 18. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer.
    Xu B; Wang N; Wang X; Tong N; Shao N; Tao J; Li P; Niu X; Feng N; Zhang L; Hua L; Wang Z; Chen M
    Prostate; 2012 Aug; 72(11):1171-8. PubMed ID: 22161865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
    Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
    Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.